Quantum-Si reported 2025 revenue of $2.4 million and positioned 2026 as a "transition year" focused on developing its Proteus platform, targeting a late-2026 launch. The company ended 2025 with $215.8 million in cash. Management expects approximately $1 million revenue in 2026, with adjusted operating expenses capped at $98 million and cash usage at $93 million, sufficient to fund operations into Q2 2028. The company added 17 new placement customers in 2025 through an expanded instrument access programme. Quantum-Si is building a publication pipeline and developing new applications, including clinical proteomics and rapid pathogen detection, to drive consumable utilization. CEO Jeff Hawkins said the strategic focus on Proteus will enable a stronger commercial ramp from 2027 onwards.

Quantum-Si, a proteomics technology company, reported fourth quarter 2025 revenue of $451,000 and full-year revenue of $2.4 million. The company announced its next-generation Proteus platform will be priced at $425,000. For 2026, Quantum-Si provided conservative guidance of approximately $1 million in revenue, reflecting strategic decisions to support Proteus's launch. These include offering upgrade credits on current Platinum Pro system sales and continuing placement programmes, which will moderate near-term revenue but position the platform for stronger long-term adoption. The company reported a full-year 2025 net loss of $101.3 million, including $18.7 million in one-time litigation charges. Adjusted total operating expenses decreased to $86.3 million from $99 million year-over-year. Quantum-Si held $215.8 million in cash and investments as of December 31, 2025, providing runway into second quarter 2028.